AN OVERVIEW OF BACTERIOPHAGE THERAPY OVER ANTIBIOTICS; AS AN ALTERNATIVE FOR CONTROLLING BACTERIAL INFECTIONS

被引:3
作者
Prabhurajeshwar, C. [1 ]
Desai, P. Pramod [2 ]
Waghmare, Tathagat [3 ]
Rashmi, S. B. [4 ]
机构
[1] Davangere Univ, Dept Biotechnol, Davangere 577002, Karnataka, India
[2] Walchand Inst Technol, Dept Biotechnol, Solapur 413006, Maharashtra, India
[3] Lokmangal Coll Agr Biotechnol, Dept Biotechnol, Solapur 413255, Maharashtra, India
[4] Mandya Inst Med Sci, Dept Biotechnol, Mandya 571401, Karnataka, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH | 2020年 / 11卷 / 03期
关键词
Bacteriophage; Food-borne; Infection; Pathogen; Therapeutic agent; Phage therapy; PHAGE THERAPY; T7; DNA; VIRUS; CELL;
D O I
10.13040/IJPSR.0975-8232.11(3).993-06
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bacteriophages are particular infective agents of diverse bacteria. They are separated into different groups according to their life cycle. The lytic phages kill their host cells; this property can be applied for the selective elimination of pathogenic bacteria. The first bacteriophage treatment was described one hundred years ago, and phage therapy had been extensively used until the Second World War. Upon the appearance of antibiotics, the medical application of phages retrograded in most parts of the world. In the last decades, owing to the costs of development of new antibiotics and the rapid emergence of multidrug-resistant bacteria, this old approach was revitalized and phage-based treatment was legalized from the middle of the last decade. Here, they summarize the current knowledge on phage therapy, its advantages and potential drawbacks. The current status of phage therapy against food-borne, animal and human pathogens is also presented. Among these, special focus is set on phages E. Amy of Staphylococcus aureus, Salmonella typhimurium and Listeria monocytogenes. Phage cocktails against Listeria monocytogenes and E. amylovora have already been commercialized.
引用
收藏
页码:993 / 1006
页数:14
相关论文
共 42 条
  • [1] Abedon Stephen T, 2011, Bacteriophage, V1, P46, DOI 10.4161/bact.1.1.13980
  • [2] Abhilash M, 2008, INTERNET J ALTERNATI, V7
  • [3] Frequency of morphological phage descriptions in the year 2000
    Ackermann, HW
    [J]. ARCHIVES OF VIROLOGY, 2001, 146 (05) : 843 - 857
  • [4] Bacteriophage-bacteriophage interactions in the evolution of pathogenic bacteria
    Boyd, EF
    Davis, BM
    Hochhut, B
    [J]. TRENDS IN MICROBIOLOGY, 2001, 9 (03) : 137 - 144
  • [5] Here a virus, there a virus, everywhere the same virus?
    Breitbart, M
    Rohwer, F
    [J]. TRENDS IN MICROBIOLOGY, 2005, 13 (06) : 278 - 284
  • [6] CAMPBELL AM, 1962, ADV GENET, V11, P101
  • [7] Prophage genomics
    Canchaya, C
    Proux, C
    Fournous, G
    Bruttin, A
    Brüssow, H
    [J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2003, 67 (02) : 238 - +
  • [8] d'Herelle F, 1917, CR HEBD ACAD SCI, V165, P373
  • [9] Bacteriophage penetration in vertebrates
    Dabrowska, K
    Switala-Jelen, K
    Opolski, A
    Weber-Dabrowska, B
    Gorski, A
    [J]. JOURNAL OF APPLIED MICROBIOLOGY, 2005, 98 (01) : 7 - 13
  • [10] Bacteriophage Therapy: Exploiting Smaller Fleas
    Deresinski, Stan
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (08) : 1096 - 1101